Literature DB >> 15024961

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography.

William E Klunk1, Henry Engler, Agneta Nordberg, Brian J Bacskai, Yanming Wang, Julie C Price, Mats Bergström, Bradley T Hyman, Bengt Långström, Chester A Mathis.   

Abstract

The steep rise in the incidence of Alzheimer's disease (AD) has further added to the considerable public health burden caused by aging of the United States population. Among the most characteristic pathologic hallmarks of AD are neuritic plaques and neurofibrillary tangles. The capability to use positron emission tomography and selective markers for amyloid protein deposition promises to substantially alter the way we diagnosis and manage patients who have AD.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 15024961     DOI： 10.1016/s1052-5149(03)00092-3

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN： 1052-5149            Impact factor:   2.264


  20 in total

1.  Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?

Authors:  Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

Review 2.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 3.  Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience.

Authors:  Anand Kumar; Olusola Ajilore; Vladimir Kepe; Jorge R Barrio; Gary Small
Journal:  Int J Geriatr Psychiatry       Date:  2008-06       Impact factor: 3.485

4.  Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

Authors:  R J Haier; K Head; E Head; I T Lott
Journal:  Neuroimage       Date:  2007-10-12       Impact factor: 6.556

Review 5.  [Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment].

Authors:  H-J Gertz; A Kurz
Journal:  Nervenarzt       Date:  2011-09       Impact factor: 1.214

6.  Development and screening of contrast agents for in vivo imaging of Parkinson's disease.

Authors:  Krista L Neal; Naomi B Shakerdge; Steven S Hou; William E Klunk; Chester A Mathis; Evgueni E Nesterov; Timothy M Swager; Pamela J McLean; Brian J Bacskai
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

7.  PET imaging of garbage protein in Alzheimer's disease: does it require reappraisal of brain PET analysis?

Authors:  Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05       Impact factor: 9.236

Review 8.  Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B.

Authors:  Keith A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

9.  A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.

Authors:  Sergey V Matveev; Hans Peter Spielmann; Brittney M Metts; Jing Chen; Fredrick Onono; Haining Zhu; Stephen W Scheff; Lary C Walker; Harry LeVine
Journal:  J Neurochem       Date:  2014-07-28       Impact factor: 5.372

10.  Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

Authors:  Rebecca F Rosen; Brian J Ciliax; Thomas S Wingo; Marla Gearing; Jeromy Dooyema; James J Lah; Jorge A Ghiso; Harry LeVine; Lary C Walker
Journal:  Acta Neuropathol       Date:  2009-08-19       Impact factor: 17.088
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.